|
|
PLGA |
|
Vaxjo ID |
225 |
|
Vaccine Adjuvant Name |
PLGA |
|
Adjuvant VO ID |
VO_0005684
|
|
Description |
Shrimp anti-lipopolysaccharide factor (SALF) is an antimicrobial peptide with reported anticancer activities, including suppression of tumor progression. |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
biodegradable poly(DL-lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) |
|
Structure |
Antimicrobial peptide |
|
Preparation |
The paper describes the preparation of a vaccine comprising SALF in conjunction with inactivated murine bladder carcinoma cells (MBT-2) lysate, but not the preparation of SALF itself. |
|
Dosage |
The paper states that immunization of 7, 14, and 21-day-old mice was performed, but specific dosage of SALF is not provided in the abstract. |
|
Function |
The hybrid NPs induced antibody and Th1/Th17 immune responses that were similar in quality and magnitude to the response induced by DDA/TDB liposomes, showing that the adjuvant properties of DDA/TDB are maintained in the PLGA hybrid matrix. Activates NLRP3 inflammasome and forms a depot for slow antigen release. [PMC5192354] |
| References |
Gutjahr et al., 2016: Gutjahr A, Phelip C, Coolen AL, Monge C, Boisgard AS, Paul S, Verrier B. Biodegradable Polymeric Nanoparticles-Based Vaccine Adjuvants for Lymph Nodes Targeting. Vaccines. 2016; 4(4); . [PubMed: 27754314].
Huang et al., 2015: Huang HN, Rajanbabu V, Pan CY, Chan YL, Chen JY, Wu CJ. Enhanced Control of Bladder-Associated Tumors Using Shrimp Anti-Lipopolysaccharide Factor (SALF) Antimicrobial Peptide as a Cancer Vaccine Adjuvant in Mice. Marine drugs. 2015; 13(5); 3241-3258. [PubMed: 26006716].
|
|
